Search

Displaying results 3271 - 3280 of 8196 in total
  1. Drug

    Dexchlorpheniramine

    go.drugbank.com/drugs/DB13679
    Investigational

    It is an antihistamine drug with anticholinergic (drying) and sedative actions. It disrupts histamine signaling by competing with histamine for cell receptor sites on effector cells.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  2. Drug

    Pacritinib

    go.drugbank.com/drugs/DB11697
    ApprovedInvestigational

    [L40793] The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia vera or essential thrombocythemia. … Pacritinib is an inhibitor of both wild-type and mutant (V617F) JAK2, as well as FMS-like tyrosine kinase 3 (FLT3), which was granted accelerated approval by the FDA in February 2022 for the treatment

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 Inducers
  3. Drug

    CERE-110

    go.drugbank.com/drugs/DB05898
    Investigational

    CERE-110 is a gene-therapy product that involves in vivo delivery of nerve growth factor (NGF) genes through an adeno-associated viral vector (AAV) delivery system.

  4. Drug

    Maxy-G34

    go.drugbank.com/drugs/DB05718
    Investigational

    MAXY-G34 is a pegylated variant of human granulocyte-colony stimulating factor (G-CSF). This variant contains multiple non-naturally occurring lysines that have been introduced into alpha helixes of wild type human G-CSF as PEGylation si...

  5. Drug

    Pilaralisib

    go.drugbank.com/drugs/DB11772
    Investigational

    Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K).

  6. Drug

    CTx-PDE6b

    go.drugbank.com/drugs/DB17858
    Investigational

    Being commercialied by Coave Therapeutics, it is being investigated for the treatment of retinitis pigmentosa due to _PDE6b_ gene mutations.[L46757] … CTx-PDE6b is an adeno-associated virus (AAV) based gene therapy designed to deliver a full-length non-mutated copy of the functional human _PDE6b_ gene.

  7. Drug

    Gliclazide

    go.drugbank.com/drugs/DB01120
    ApprovedInvestigational

    Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). … Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesSynonyms: 1-(3-azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea, 1-(hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)urea
  8. Drug

    Ferric pyrophosphate citrate

    go.drugbank.com/drugs/DB13995
    Approved

    Free iron presents several side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of interactions of iron in plasma.

  9. Drug

    Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB10076
    Approved

    *H. influenzae* is a Gram-negative coccobacillus that can cause infections including sepsis and meningitis.

  10. Drug

    Parecoxib

    go.drugbank.com/drugs/DB08439
    ApprovedInvestigational

    As it is injectable, it can be used perioperatively when patients are unable to take oral medications.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamide